Sun Pharmaceutical (SUNPHARMA) — Financial Results

Sun Pharmaceutical reported Q2 FY26 consolidated sales of ₹144,052 million (8.6% YoY growth) with net profit of ₹31,180 million (2.6% YoY growth). EBITDA grew 14.9% to ₹45,271 million, achieving 31.3% margins. Global Innovative Medicines surged 16.4% to USD 313 million, with U.S. innovative medicines now exceeding generics. India formulations grew 11%, maintaining #1 market position with 8.3% share. U.S. business declined 4.1% due to generic competition and lower lenalidomide sales, partially offset by ILUMYA, CEQUA, and ODOMZO growth. The company plans ILUMYA psoriatic arthritis filing in H2 FY26 and launched semaglutide generics in Canada.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How does this financial results affect Sun Pharmaceutical Industries Limited's outlook?" "What did Sun Pharmaceutical Industries Limited announce on 11 November 2025?" "Is this positive or negative for SUNPHARMA?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 11 November 2025

SHRIRAMFIN Shriram Finance Limited Corporate Action APOLLOHOSP Apollo Hospitals Enterprise Limited Financial Results TATAPOWER Tata Power Company Limited Financial Results TATAPOWER Tata Power Company Limited Financial Results TATAPOWER Tata Power Company Limited Financial Results AXISBANK Axis Bank Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.